BioCentury
ARTICLE | Company News

Lupin gets newly approved drug in Symbiomix deal

October 11, 2017 11:23 PM UTC

Lupin Ltd. (NSE:LUPIN; BSE:500257) said it acquired anti-infectives company Symbiomix Therapeutics LLC (Newark, N.J.). The deal gives the Indian pharma rights to Solosec secnidazole, which FDA approved last month to treat bacterial vaginosis.

Symbiomix shareholders received $50 million up front and are eligible for another $100 million in milestones, plus contingent payments...